Short Report on Halozyme Therapeutics Stock

By Harris Dyer • Tuesday, August 01 13:32 • Permanent Link

Halozyme Therapeutics logged a -0.9% change during today's afternoon session, and is now trading at a price of $42.57 per share. The S&P 500 index moved -0.0%. HALO's trading volume is 355,605 compared to the stock's average volume of 1,189,556.

Halozyme Therapeutics trades -15.87% away from its average analyst target price of $50.6 per share. The 10 analysts following the stock have set target prices ranging from $26.0 to $72.0, and on average have given Halozyme Therapeutics a rating of buy.

Anyone interested in buying HALO should be aware of the facts below:

Halozyme Therapeutics's current price is 1099.3% above its Graham number of $3.55, which implies that at its current valuation it does not offer a margin of safety
Halozyme Therapeutics has moved -1036.9% over the last year, and the S&P 500 logged a change of 1216.7%
Based on its trailing earnings per share of 1.33, Halozyme Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 32.0 while the S&P 500 average is 15.97
HALO has a forward P/E ratio of 11.7 based on its forward 12 month price to earnings (EPS) of $3.65 per share
The company has a price to earnings growth (PEG) ratio of 0.64 — a number near or below 1 signifying that Halozyme Therapeutics is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 85.14 compared to its sector average of 4.16
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
Based in San Diego, the company has 393 full time employees and a market cap of $5.61 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.